Background: Various polichemotherapy regimens, including either high-or intermediate-dose Ara-C, are generally utilized to reinduce remission in relapsed AML patients. After achieving second CR, bone marrow transplantation (either allogeneic or autologous) represents the treatment of choice for eligible patients, with the aim of prolonging remission duration and improving disease-free survival.
Introduction
Currently, 60%-80% of adult patients and 90% of children with newly diagnosed acute myeloid leukemia (AML) may achieve complete remission (CR) after induction chemotherapy [1] [2] [3] [4] [5] . Nevertheless, recurrence of the disease remains a major problem. A second CR may be achieved in more than 50% of relapsed patients by the use of one of several chemotherapy programs, most of which include high-dose cytarabine (Ara-C) alone or combined with other drugs; the duration of these remissions is, however, quite short and the probability of prolonged survival with conventional chemotherapy is very poor [6] [7] [8] [9] [10] . Intensive postremission treatments including high-dose chemo-radiotherapy followed by allogeneic or autologous stem cell reinfusion have been widely utilized to increase the percentage of long-term survivors in second CR [11, 12] . A leukemia-free survival (LFS) of approximately 35% at 5 years has been reported by the International Bone Marrow Transplantation Registry (IBMTR) after allogeneic bone marrow transplantation (BMT) [13] . For patients without HLA identical siblings, autologous BMT could represent an alternative treatment; the last retrospective analysis from the European Bone Marrow Transplantation (EBMT) registry performed on 331 patients autografted in second CR shows a LFS of 33% at 8 years [14] . Furthermore, our results in AML patients autografted in second CR using the BAVC conditioning regimen [15] seem very encouraging and have recently been confirmed on a larger series of patients with a longer follow-up [16] .
In 1988, our group started a therapeutic trial of intermediate-dose Ara-C and mitoxantrone plus etoposide (MEC) in patients with advanced AML, which showed that this regimen could be an effective antileukemic treatment with acceptable toxicity. The CR rate was, in fact, 77% for patients treated in first relapse, and more than 90% in those with a first remission lasting more than 6 months (late relapse) [17, 18] . Our two previous reports dealt mainly with the feasibility, toxicity and antileukemic activity of the MEC regimen, in particular with regard to CR rate and duration in different categories of 'high-risk' AML patients.
The objective of the present analysis was to evaluate the complete history of the disease in a more homo-geneous and consecutive cohort of 50 AML patients, starting from time of first relapse. In particular, our aim was to determine: 1) the real probability of becoming long-term survivors for the overall population assigned, at the time of relapse, to a theoretically ideal treatment -intensive chemotherapy to induce second CR followed by a myeloablative post-consolidation procedure; 2) the fraction of patients who actually will receive a transplant in second CR. Determination of the latter would be particularly useful for obtaining essential figures with respect to the controversial issue of riming of autograft in AML -whether in first CR or after relapse.
Patients and methods

Patients
From 1988 until 1993, all patients referred to our institution for AML in first hematological relapse entered the study. Eligibility criteria were: age less than 70 years, diagnosis of AML excluding M3 according to the French-American-Brinsh (FAB) classification, performance status <3 according to the World Health Organization (WHO) scale [19] , bilirubin less than 3 mg/dl, creatinine less than 2 mg/dl, left ventricular ejection fraction greater than 50%, and no evidence of active infection at entry.
Written informed consent was obtained from patients or from parents of patients under 18 years of age.
The clinical characteristics of patients are detailed in Table 1 . The post-remission treatments administered in first CR are detailed in Table 2 .
Definition of response CR was defined as a cellular marrow with less than 5% of blasts, a normalization of peripheral blood (PB) counts and a disappearance of all clinical features related to leukemia persisting for more than 1 month. A patient was defined as refractory to the MEC induction regimen if either progression of disease during induction or a persistent bone marrow (BM) blastosis on day +28 was shown. Relapse was defined by a BM blastosis greater than 25% observed at 2 consecutive BM aspirates performed with a 1-week interval.
Treatment
MEC regimen
Consisted of a single 6-day course of mitoxantrone (6 mg/m 2 ), etoposide (80 mg/m 2 ) and intermediate-dose Ara-C (1 g/m 2 ), administered daily on days 1 through 6. Patients achieving CR received a consolidation course with the same drugs at the same dosage for 4 days. The drugs were administered according to modalities previously described [18] .
Either autologous or allogeneic (if an HLA-identical sibling was available) transplant was planned for all patients still in second CR after recovery from the consolidation MEC cycle, if standard eligibility criteria for receiving myelosuppressive treatments were fulfilled.
Autologous BMT
The techniques of marrow collection, cryopreservan'on and reinfusion have been previously described [20] . Marrow was collected immediately prior to the start of pretransplant chemotherapy in all but one patient, who received marrow harvested in first CR. Thirteen of 15 patients received BAVC [15] in a preparatory regimen, followed after a 2-day rest by unpurged bone marrow reinfusion. Abbreviations: FAB -French-American-British classification; CR -complete remission; ABMT -autologous bone marrow transplantation; BMT -allogeneic bone marrow transplantation; '3 + 7' -daunorubicine (3 days) plus cytosine-arabinoside (7 days); ICEidarubicine (days 1-3-5) plus etoposide (days 1 to 5) plus cytosinearabinoside (days 1 to 10). 
Abbreviations: Pts -patients; ABMT -autologous bone marrow transplantation; BMT -allogeneic bone marrow transplantation; Ara-C -cytosine-arabinoside; Amsa -amsacrine; DNR -daunorubicine; DAT -daunorubicine, Ara-C, 6-thioguanine; NOVIAmitoxantrone, etoposide, Ara-C; VP-16 -etoposide; '2 + 5' -daunorubicine (2 days) plus cytosine-arabinoside (5 days); Mitomitoxantrone; i.d. -intermediate-doses; Adria -adriamycine; 6-TG -6-thioguanine.
Two patients received the busulfan-cyclophosphamide regimen [21] because of a previous meningosis in one, and autograft in first CR with BAVC regimen in the second. The patients occupied double rooms, and were treated with a central venous catheter placed for administration of chemotherapy, blood products, and fluids. All received prophylactic oral antibiotics (ciprofloxacine) when neutrophil counts fell below 0.5 x lO'/l. Acyclovir i.v. 15 mg/kg/die was started on day +1 to prevent herpes virus infection. Intravenous broad spectrum antibiotics were given for fever during aplasia, with the addition of amphotericin B if fever persisted longer than 5 days or if fungal infection was documented.
All blood products administered were irradiated with 20 Gy before infusion to prevent graft-wms-host reactions.
Allogeneic BMT
The patients occupied single rooms. The preparatory regimen consisted of busulfan administered orally for 4 consecutive days for a total dose of 16 mg/kg and cyclophosphamide (Cy) administered intravenously at a daily dose of 60 mg/kg for 2 consecutive days [21] . The donor bone marrow was infused 2 days after the final dose of Cy without manipulation. Reverse isolation and ciprofloxacine were started on the day of infusion and a sterile diet was instituted during neutropenia. To prevent graft-vwsus-host-disease (GVHD) cyclosporine plus four doses of methotrexate were given. Antimicrobial and transfusional treatments were similar to that previously described for autografted patients.
Statistical analysis
Overall survival (OS) and event-free survival (EFS) were calculated from the start of induction therapy: events considered were induction failure and death for OS, plus relapse for EFS. Disease-free survival (DFS) was evaluated from second CR, and the events considered were relapse and death.
The significance of differences observed in proportion was tested by chi-square statistics. Survival curves were calculated according to the Kaplan-Meier method, with results expressed as percentages ± standard error (22) . The significance of differences between actuarial curves was estimated by the log-rank test, and two-sided lvalues were used throughout [23] .
Toxicity
All toxicities were graded according to the WHO grading system [19] .
Results
Outcome
Of 50 patients enrolled in the study, 34 (68%) achieved CR, 13 (26%) were refractory but survived induction, and 3 (6%) died during induction of infection with hypoplastic marrow. The treatment-related toxicities were similar to those previously reported by our group with the MEC regimen [17, 18] . The remission rate was 41% (7 of 17 cases) for patients with a first CR lasting <6 months (early relapses) versus 82% (27 of 33 cases) for the remaining (late relapses) (P < 0.01).
In the subgroup of 12 patients who were transplanted in first CR, the remission rate was 55% (5/9 cases) for late relapses and 33% (1/3 cases) for early relapses, with an overall remission rate of 50% (6/12) versus 73% (28/38) for the non-transplanted patients [P-not significant (N.S.)].
Eighteen of the 34 patients in CR after MEC therapy (53%) were not transplanted because of persistent toxic effects (6 infections and 1 liver toxicity), refusal (2 patients), medical decision (3 patients) or relapse prior to the time when logistical problems had to be finalized for transplant (6 patients); 16 (47%) received high-dose treatment with either autologous (15) or allogeneic (1) BMT (Table 3) . Only 1/16 transplanted patients had received a previous ABMT in first CR
Duration of response
For the group as a whole the median duration of second CR was 12 months, and it lasted up to 27 months in the transplanted group (16 patients) versus 4 months in the non-transplanted group (18 patients) ( Table 4) .
In particular, 14 of the 18 non-transplanted patients relapsed after a median of 3.5 months from second CR (range, 1 to 12), and 4 are in continuous CR with a follow-up of 2, 20, 37 and 49 months, respectively. None of them received any further treatment. The median age in this group was 47 years (range, 10 to 69), and the median duration of the first CR was 10 months (range, 5 to 48), lasting > 6 months in 15/18 cases.
Of the 16 transplanted patients, 7 are in continuous CR (6 autologous, 1 allogeneic), with a median followup of 51 months (range, 14 to 69). Eight patients relapsed in the bone marrow at a median of 15 months (range 6-31) after achievement of second CR. The median age of this group was 26 years, ranging from 9 to 54; 9 of the patients were female. The median duration of first CR was 15 months (range 1 to 50), lasting more than 6 months in 12/16 patients. Autograft was performed in 15/16 patients after a median time of 2 months (range 1-4) from reaching second CR. The conditioning regimens were well tolerated and slight nausea and vomiting occurred during administration of chemotherapy. A median of 1.3 x 10 8 (range, 0.4 to 3.4) nucleated marrow cells per kilogram of body weight were cryopreserved and reinfused. During aplasia, three patients developed severe oral mucositis (maximum WHO degree 4) which resolved at the time of bone marrow engraftment. In 5 cases a parenteral nutrition was required. All patients had fever and started antibiotic treatment: in 8 cases positive blood cultures for bacteria were documented, in particular, staphylococcus (3 cases), streptococcus, enterococcus, bacteroides, serratia and fusobacterium (one case each). Antifungine therapy was administered in 8 cases because of persistent fever: in one patient a pulmonary fungal infection was documented which resolved after amphotericin B treatment.
One patient showed no evidence of engraftment and on day +97 received a second infusion of bone marrow harvested in first CR. One patient, previously autografted in first CR and conditioned with Bu + Cy, died on day 106 of hemorrhage.
Recovery is evaluable in 13/15 patients. The median time required to attain an absolute neutrophil count in excess of 0.5 x 10 9 /l was 29 days (range, 24 to 64). A sustained platelet count exceeding 20 x 1071 was reached after a median of 61 days (range, 11 to 345).
The allografted patient, transplanted 7 months after achieving second CR, received 3.4 x 10 8 cells per kilogram b.w. and obtained engraftment on day +14 for neutrophils >0.5 x 10 9 /l and on day +17 for platelets >50xl0 9 /l.
Survival
OS and EFS projected at 70 months for the entire group of 50 patients were 29% (±7%) and 19% (± 6%), respectively ( Figure 1 ). The univariate evaluation of prognostic factors showed a clear influence of first CR duration on the outcome: EFS projected at 56 months from the start of MEC therapy was 12% (± 8%) for early relapses versus 23% (± 8%) for late relapses (P-0.04) (Figure 2 ). The overall probability of DFS for the 34 patients achieving second CR was 29% (±8%) projected at 69 months (Figure 3 ), in particular, 41% (± 13%) at 69 months for the transplanted group and 18% (±9%) at 49 months for the remaining (P-0.007) (Figure 4 ).
Discussion
In this study 34/50 (68%) AML patients who underwent the MEC regimen in first relapse achieved a second CR. Treatment-related toxicity was fairly good, resulting in an induction death rate of only 6%. These data confirm results previously reported by our group with the MEC regimen in relapsed AML on a larger series of patients and with a longer follow-up [17, 18] . First CR duration is strictly correlated with the possibility of attaining a new complete remission. The 25 patients with first CR duration >6 months had a statistically significant higher CR rate: 82% as compared to 41% for patients relapsing within 6 months. Therefore, both OS and EFS are significantly poorer in the group of patients with a shorter first CR duration (12% and 12% at 70 months, respectively) versus patients with a longer first CR duration (38% and 23% at 56 months, respectively) ( Table 5) .
Only one-half of remitters were eligible for aggressive post-consolidation treatments. This means that less than one-third of the initial group of patients actually received the planned myeloablative treatment in second CR. This point should be taken into account when evaluating the different impact of ABMT in the treatment strategy of AML if utilized in first CR or deferred after first relapse.
Patients receiving high-dose treatment show a higher probability of becoming long-term disease-free survivors: 7/16 (44%) transplanted patients are in continuous CR (CCR) after a median follow-up of 51 months, with a DFS of 41% projected at 69 months versus 18% at 49 months in non-transplanted patients (P = 0.007). Obviously, this is a non-randomized study and a retrospective comparison cannot confirm a superiority for ABMT over chemotherapy in second CR AML, mainly because of the automatic assignment of early failures to the chemotherapy group. However, this experience underscores the good results already reported by our group with the BAVC regimen in second CR AML, confirming the antileukemic efficacy of a treatment combining MEC with transplant procedures, as well as the possibility of obtaining a significant number of long-term survivors in AML also after first relapse [24] .
Results reported by other groups in second CR vary widely: DFS ranges from 14% up to a maximum of 50% [11] . Obviously, these results reflect the heterogeneity of patients treated in individual groups, with different chemotherapy schedules and different clinical characteristics. For this reason an overall comparison of these data is, in our opinion, very difficult. A larger analysis for autograft in AML in second CR has been reported by Gorin et al. on 331 patients from the EBMT registry, showing a global LFS of 33% at 8 years [11, 14] . Results from our single-centre experience with a transplanted group of patients may be considered similar.
It is worth noting that, in our study, more than 50% of complete responders to MEC were not eligible for BMT. The outcome of this group is very poor, and alternative strategies should be investigated for patients who are ineligible for intensive chemotherapy programs after achievement of a second CR [25] [26] [27] [28] [29] [30] [31] .
